|
05 Dec 2019 |
Algernon Pharmaceuticals’ NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110%
|
|
05 Dec 2019 |
Osivax Enters Agreement with U.S. National Institutes of Health to Test Universal Flu Vaccine Candidate
|
|
05 Dec 2019 |
ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
|
|
05 Dec 2019 |
Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis
|
|
04 Dec 2019 |
Innovative Cellular Therapeutics Announces FDA Clearance of IND for its Dominant Negative PD-1 “Armored” Next Generation CAR-T Cell Therapy
|
|
04 Dec 2019 |
Lannett Announces Positive Results From Human Clinical Trial Of Biosimilar Insulin Glargine Versus US Lantus®
|
|
04 Dec 2019 |
Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab
|
|
04 Dec 2019 |
Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM
|
|
04 Dec 2019 |
Bristol-Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for ORENCIA® (abatacept) to Help Prevent Acute Graft-Versus-Host Disease, a Potentially Life-Threatening Complication After Stem Cell Transplant
|
|
04 Dec 2019 |
Cerevance Initiates Phase 2 Trial of CVN424 for Parkinson’s Disease
|
|
04 Dec 2019 |
Bio-Thera Solutions Announces NMPA approval of IND Application to Initiate Phase I Clinical Trial for BAT2206, a Proposed Biosimilar of Stelara® (Ustekinumab)
|
|
04 Dec 2019 |
ImmunityBio Granted FDA Breakthrough Therapy Designation for N-803 IL-15 Superagonist in Non-Muscle Invasive Bladder Cancer
|
|
04 Dec 2019 |
Gatehouse Bio collaborates with AstraZeneca to accelerate new drug discovery
|
|
04 Dec 2019 |
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy
|
|
04 Dec 2019 |
BridgeBio Pharma’s Origin Biosciences Initiates Rolling Submission of New Drug Application with the U.S. FDA for BBP-870 for the Treatment of MoCD Type A
|
|
04 Dec 2019 |
Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)
|
|
04 Dec 2019 |
Immunomedics Resubmits Biologics License Application to the FDA for Sacituzumab Govitecan
|
|
04 Dec 2019 |
Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo
|
|
04 Dec 2019 |
Atreca Announces FDA Clearance of Investigational New Drug Application for ATRC-101
|
|
04 Dec 2019 |
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia
|
